References
- Riggs BL, Melton LJ 3rd. The prevention and treatment of osteoporosis. New Eng J Med 1992;327:620–7
- Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005–10
- Gregg EW, Cauley JA, Seeley DG, Ensrud KE, Bauer DC. Physical activity and osteoporotic fracture risk in older women [Study of Osteoporotic Fractures Research Group]. Ann Intern Med 1998;129:81–8
- Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997;103(2A):20S–26S
- Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16:87–116
- Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. [The Alendronate Phase III Osteoporosis Treatment Study Group]. New Engl J Med 1995;333:1437–43
- Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. New Engl J Med 2000;343:604–10
- Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693–700
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535–41
- Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
- Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999;9:461–8
- Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Rev 2002;23:508–16
- Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000;22:15–28
- Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:1–12
- Greenspan SL, Bone G 3rd, Schnitzer TJ et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17: 1988–95
- Simon JA, Lewiecki M, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
- Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M et al. Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med 2000;160:517–25
- Fosamax Prescribing Information. Physicians’ desk reference®, 55th edn. Montvale, NJ: Medical Economics Co; 2001:1930–36
- Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. Chichester, UK: John Wiley & Sons; 1996:57
- Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002;77:1044–52
- Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterol 1997;112: 1448–56
- National Prescription Audit Plus, and National Disease and Therapeutic Index, Fosamax Total Prescriptions, January 2001 – December 2001. IMS Health, Plymouth Meeting, Pa. [online] Available from http://www.imshealth.com/ [Accessed 9 September 2002]
- Schnitzer TJ. Update on alendronate for osteoporosis: once-weekly dosing. Expert Opin Pharmacother 2001;2:1461–72
- Data on file, Merck & Co., Inc
- Tonino RP, Meunier PG, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. J Clin Endocrinol Metab 2000;85:3109–15